BGI Tech has launched the Agilent SureSelectXT Human Methyl-Seq service, a cost-effective approach for analyzing the methylation status of cytosine sites of specific regions within the human genome.
This approach combines Agilent SureSelect target region enrichment platform with bisulfite sequencing- the gold standard for DNA methylation analysis, and enables the most comprehensive coverage of disease related regions to accelerate your epigenetic studies and complex disease research.
84Mb design, 3.7M CpGs
known cancer tissue specific DMRs
CpG islands shelves (~4kb away from islands)
DNase I hypersensitive sites
Ensembl regulatory features
Cost-effective to explore the methylation status of specific regions
Single base resolution
Excellent concordance with WGBS data
Thorough investigation of known and novel DMRs
Epigenome-wide association studies (EWAS)
Cell development study
Signaling pathway analysis